Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal

Bibliography

• Rostron B. Smoking-attributable mortality by cause in the United States: revising the CDC’s data and estimates. Nicotine Tob Res 2013;15(1):238-46
   PubMed Web of Science ®Google Scholar
• (CDCP) CfDCaP. Quitting smoking among adults–United States, 2001-2010. MMWR Morb Mortal Wkly Rep 2011;60(44):1513-19
   PubMedGoogle Scholar
• Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA 2014;311(2):193-4
   PubMed Web of Science ®Google Scholar
• Garvey AJ, Bliss RE, Hitchcock JL, et al. Predictors of smoking relapse among self-quitters: a report from the Normative Aging Study. Addict Behav 1992;17(4):367-77
   PubMed Web of Science ®Google Scholar
• Hughes JR. Tobacco withdrawal in self-quitters. J Consult Clin Psychol 1992;60(5):689-97
   PubMed Web of Science ®Google Scholar
• Ashare RL, Wileyto EP, Perkins KA, Schnoll RA. The first 7 days of a quit attempt predicts relapse: validation of a measure for screening medications for nicotine dependence. J Addict Med 2013;7(4):249-54
   PubMed Web of Science ®Google Scholar
• Conn PJ, Roth BL. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 2008;33(9):2048-60
   PubMed Web of Science ®Google Scholar
• Lerman C, LeSage MG, Perkins KA, et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 2007;6(9):746-62
   PubMed Web of Science ®Google Scholar
• Hare TA, Camerer CF, Rangel A. Self-control in decision-making involves modulation of the vmPFC valuation system. Science 2009;324(5927):646-8
   PubMed Web of Science ®Google Scholar
• Kouneiher F, Charron S, Koechlin E. Motivation and cognitive control in the human prefrontal cortex. Nat Neurosci 2009;12(7):939-45
   PubMed Web of Science ®Google Scholar
• Perkins K, Stitzer M, Lerman C. Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology (Berl) 2006;184(3-4):628-36
   PubMed Web of Science ®Google Scholar
• McKee SA. Developing human laboratory models of smoking lapse behaviour for medication screening. Addic Biol 2009;14(1):99-107
   PubMed Web of Science ®Google Scholar
• Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986;43(3):289-94
   PubMed Web of Science ®Google Scholar
• Patterson F, Jepson C, Loughead J, et al. Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend 2010;106(1):61-4
   PubMed Web of Science ®Google Scholar
• Brady KT, Gray KM, Tolliver BK. Cognitive enhancers in the treatment of substance use disorders: clinical evidence. Pharmacol Biochem Behav 2011;99(2):285-94
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology 2013;64:452-63
   PubMed Web of Science ®Google Scholar
• Davis JA, James JR, Siegel SJ, Gould TJ. Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. J Neurosci 2005;25(38):8708-13
   PubMed Web of Science ®Google Scholar
• Myers CS, Taylor RC, Moolchan ET, Heishman SJ. Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray. Neuropsychopharmacology 2008;33(3):588-98
   PubMed Web of Science ®Google Scholar
• Raybuck JD, Portugal GS, Lerman C, Gould TJ. Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. Behav Neurosci 2008;122(5):1166-71
   PubMed Web of Science ®Google Scholar
• Loughead J, Ray R, Wileyto EP, et al. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry 2010;67(8):715-21
   PubMed Web of Science ®Google Scholar
• Le Foll B, Goldberg SR. Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl) 2006;184(3-4):367-81
   PubMed Web of Science ®Google Scholar
• Corringer PJ, Le Novere N, Changeux JP. Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol 2000;40:431-58
   PubMed Web of Science ®Google Scholar
• Tuesta LM, Fowler CD, Kenny PJ. Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behaviour. Biochem Pharmacol 2011;82(8):984-95
   PubMed Web of Science ®Google Scholar
• Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998;391(6663):173-7
   PubMed Web of Science ®Google Scholar
• Changeux JP. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci 2010;11(6):389-401
   PubMed Web of Science ®Google Scholar
• Dwoskin LP, Smith AM, Wooters TE, et al. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem Pharmacol 2009;78(7):732-43
   PubMed Web of Science ®Google Scholar
• Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007;52(3):985-94
   PubMed Web of Science ®Google Scholar
• O’Connor EC, Parker D, Rollema H, Mead AN. The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology 2010;208(3):365-76
   PubMed Web of Science ®Google Scholar
• Patterson F, Jepson C, Strasser AA, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 2009;65(2):144-9
   PubMed Web of Science ®Google Scholar
• Ashare RL, McKee SA. Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers. Exp Clin Psychopharmacol 2012;20(1):63-70
   PubMed Web of Science ®Google Scholar
• Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):47-55
   PubMed Web of Science ®Google Scholar
• Hays JT, Ebbert JO, Sood A. Efficacy and safety of varenicline for smoking cessation. Am J Med 2008;121(4 Suppl 1):S32-42
   PubMed Web of Science ®Google Scholar
• Hussmann GP, Turner JR, Lomazzo E, et al. Chronic sazetidine-A at behaviourally active doses does not increase nicotinic cholinergic receptors in rodent brain. J Pharmacol Exp Ther 2012;343(2):441-50
   PubMed Web of Science ®Google Scholar
• Levin ED. Complex relationships of nicotinic receptor actions and cognitive functions. Biochem Pharmacol 2013;86(8):1145-52
   PubMed Web of Science ®Google Scholar
• Xiao Y, Fan H, Musachio JL, et al. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol 2006;70(4):1454-60
   PubMed Web of Science ®Google Scholar
• Levin ED, Rezvani AH, Xiao Y, et al. Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. J Pharmacol Exp Ther 2010;332(3):933-9
   PubMed Web of Science ®Google Scholar
• Rezvani AH, Cauley M, Sexton H, et al. Sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats. Psychopharmacology (Berl) 2011;215(4):621-30
   PubMed Web of Science ®Google Scholar
• Levin ED. Complex relationships of nicotinic receptor actions and cognitive functions. Biochem Pharmacol 2013;86(8):1145-52
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Dunbar G, Segreti AC, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 2013;38(6):968-75
   PubMed Web of Science ®Google Scholar
• Hilt D, Gawryl M, Koenig G. Evp-6124: Safety, tolerability and cognitive effects of a novel α7 nicotinic receptor agonist in alzheimer’s disease patients on stable donepezil or rivastigmine therapy. Alzheimers Dement 2009;5(4):e32
   Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006;(1):CD005593
   PubMed Web of Science ®Google Scholar
• Kimmey BA, Rupprecht LE, Hayes MR, Schmidt HD. Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats. Addiction Biol 2012. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Hopkins TJ, Rupprecht LE, Hayes MR, et al. Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology 2012;37(10):2310-21
   PubMed Web of Science ®Google Scholar
• Wilkinson DS, Gould TJ. The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice. Behav Brain Res 2011;223(1):53-7
   PubMed Web of Science ®Google Scholar
• Ashare RL, Ray R, Lerman C, Strasser AA. Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: a pilot feasibility study. Drug Alcohol Depend 2012;126(1-2):263-7
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Herman AI, Li Y, Waters AJ. Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report. Psychopharmacology (Berl) 2012;224(3):413-20
   PubMed Web of Science ®Google Scholar
• Giarola A, Auber A, Chiamulera C. Acetylcholinesterase inhibitors partially generalize to nicotine discriminative stimulus effect in rats. Behav Pharmacol 2011;22(1):1-6
   PubMed Web of Science ®Google Scholar
• Diehl A, Nakovics H, Croissant B, et al. Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial. Int J Clin Pharmacol Ther 2006;44(12):614-22
   PubMed Web of Science ®Google Scholar
• Diehl A, Nakovics H, Mutschler J, et al. Rivastigmine reduces tobacco craving in alcohol-dependent smokers. Pharmacopsychiatry 2009;42(3):89-94
   PubMed Web of Science ®Google Scholar
• Kelly DL, McMahon RP, Weiner E, et al. Lack of beneficial galantamine effect for smoking behaviour: a double-blind randomized trial in people with schizophrenia. Schizophr Res 2008;103(1-3):161-8
   PubMed Web of Science ®Google Scholar
• Samochocki M, Hoffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003;305(3):1024-36
   PubMed Web of Science ®Google Scholar
• Williams DK, Wang J, Papke RL. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem Pharmacol 2011;82(8):915-30
   PubMed Web of Science ®Google Scholar
• Berrettini WH, Doyle GA. The CHRNA5-A3-B4 gene cluster in nicotine addiction. Mol Psychiatry 2012;17(9):856-66
   PubMed Web of Science ®Google Scholar
• Timmermann DB, Sandager-Nielsen K, Dyhring T, et al. Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of alpha2- and alpha4-containing nicotinic acetylcholine receptors. Br J Pharmacol 2012;167(1):164-82
   PubMed Web of Science ®Google Scholar
• Callahan PM, Hutchings EJ, Kille NJ, et al. Positive allosteric modulator of alpha 7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates. Neuropharmacology 2013;67:201-12
   PubMed Web of Science ®Google Scholar
• Liu X. Positive allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration. Psychopharmacology 2013;230(2):203-13
   PubMed Web of Science ®Google Scholar
• Riedel G, Platt B, Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res 2003;140(1-2):1-47
   PubMed Web of Science ®Google Scholar
• Markou A. Review. Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci 2008;363(1507):3159-68
   PubMed Web of Science ®Google Scholar
• Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioural addictions. Pharmacol Biochem Behav 2012;100(4):801-10
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhou X, Zhang Q. Effectiveness and safety of memantine treatment for Alzheimer’s disease. J Alzheimers Dis 2013;36(3):445-58
   PubMed Web of Science ®Google Scholar
• Repantis D, Laisney O, Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010;61(6):473-81
   PubMed Web of Science ®Google Scholar
• Blokhina EA, Kashkin VA, Zvartau EE, et al. Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. Eur Neuropsychopharmacol 2005;15(2):219-25
   PubMed Web of Science ®Google Scholar
• Jackson A, Nesic J, Groombridge C, et al. Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking. Neuropsychopharmacology 2009;34(2):257-65
   PubMed Web of Science ®Google Scholar
• Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimer’s Dementia 2013;9(3):326-31
   PubMed Web of Science ®Google Scholar
• Myers KM, Carlezon WA Jr, Davis M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology 2011;36(1):274-93
   PubMed Web of Science ®Google Scholar
• Nandhra HS, Murphy CL, Sule A. Novel pharmacological agents targeting memory and cognition in the treatment of anxiety disorders. Hum Psychopharmacol 2013;28(6):538-43
   PubMed Web of Science ®Google Scholar
• Bado P, Madeira C, Vargas-Lopes C, et al. Effects of low-dose D-serine on recognition and working memory in mice. Psychopharmacology (Berl). 2011;218(3):461-70
   Google Scholar
• Assini FL, Duzzioni M, Takahashi RN. Object location memory in mice: pharmacological validation and further evidence of hippocampal CA1 participation. Behav Brain Res 2009;204(1):206-11
   PubMed Web of Science ®Google Scholar
• Levin ED, Slade S, Wells C, et al. D-cycloserine selectively decreases nicotine self-administration in rats with low baseline levels of response. Pharmacol Biochem Behav 2011;98(2):210-14
   PubMed Web of Science ®Google Scholar
• Santa Ana EJ, Rounsaville BJ, Frankforter TL, et al. D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation. Drug Alcohol Depend 2009;104(3):220-7
   PubMed Web of Science ®Google Scholar
• Nesic J, Duka T, Rusted JM, Jackson A. A role for glutamate in subjective response to smoking and its action on inhibitory control. Psychopharmacology (Berl) 2011;216(1):29-42
   PubMed Web of Science ®Google Scholar
• Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 2007;113(3):523-36
   PubMed Web of Science ®Google Scholar
• Ramos BP, Stark D, Verduzco L, et al. Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behaviour through inhibition of cAMP signaling in aging animals. Learn Mem 2006;13(6):770-6
   PubMed Web of Science ®Google Scholar
• Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48(2):155-65
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med 2012;85(1):45-58
   PubMedGoogle Scholar
• McKee SA, Sinha R, Potenza MN, et al. Guanfacine as a potential pharmacotherapy for stress-preciptiated smoking relapse Society for Research on Nicotine and Tobacco; Boston, MA; 2013
   Google Scholar
• Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 2014;53(2):153-73
   PubMed Web of Science ®Google Scholar
• Le Houezec J, Aubin H-J. Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence. Expert Opin Pharmacother 2013;14(14):1959-67
   PubMed Web of Science ®Google Scholar
• Logemann HN, Bocker KB, Deschamps PK, et al. The effect of noradrenergic attenuation by clonidine on inhibition in the stop signal task. Pharmacol Biochem Behav 2013;110:104-11
   PubMed Web of Science ®Google Scholar
• Chamberlain SR, Muller U, Blackwell AD, et al. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 2006;311(5762):861-3
   PubMed Web of Science ®Google Scholar
• Chamberlain SR, Del Campo N, Dowson J, et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 2007;62(9):977-84
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Spencer T, et al. Atomoxetine and Stroop Task Performance in Adult Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol 2005;15(4):664-70
   PubMed Web of Science ®Google Scholar
• Davis JA, Gould TJ. Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning. Neuropsychopharmacology 2007;32(9):2011-19
   PubMed Web of Science ®Google Scholar
• Ray R, Rukstalis M, Jepson C, et al. Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence. J Psychopharmacol (Oxf) 2009;23(2):168
   PubMed Web of Science ®Google Scholar
• Silverstone PH, Dadashova R. Atomoxetine treatment for nicotine withdrawal: a pilot double-blind, placebo-controlled, fixed-dose study in adult smokers. Ann General Psychiatry 2012;11(1):6
   PubMedGoogle Scholar
• Hughes JR, Stead LF, Hartmann-Boyce J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014;1:CD000031
   PubMed Web of Science ®Google Scholar
• Cinciripini PM, Tsoh JY, Wetter DW, et al. Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Exp Clin Psychopharmacol 2005;13(4):282-92
   PubMed Web of Science ®Google Scholar
• Jett JD, Morilak DA. Too much of a good thing: blocking noradrenergic facilitation in medial prefrontal cortex prevents the detrimental effects of chronic stress on cognition. Neuropsychopharmacology 2013;38(4):585-95
   PubMed Web of Science ®Google Scholar
• Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007;448(7154):645-6
   PubMed Web of Science ®Google Scholar
• Gourlay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther 1997;62(4):453-63
   PubMed Web of Science ®Google Scholar
• Rose JE, Corrigall WA. Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology (Berl) 1997;130(1):28-40
   PubMed Web of Science ®Google Scholar
• Shoaib M, Stolerman IP. Plasma nicotine and cotinine levels following intravenous nicotine self-administration in rats. Psychopharmacology (Berl) 1999;143(3):318-21
   PubMed Web of Science ®Google Scholar
• Coen KM, Adamson KL, Corrigall WA. Medication-related pharmacological manipulations of nicotine self-administration in the rat maintained on fixed- and progressive-ratio schedules of reinforcement. Psychopharmacology (Berl) 2009;201(4):557-68
   PubMed Web of Science ®Google Scholar
• Rauhut AS, Neugebauer N, Dwoskin LP, Bardo MT. Effect of bupropion on nicotine self-administration in rats. Psychopharmacology (Berl) 2003;169(1):1-9
   PubMed Web of Science ®Google Scholar
• George O, Lloyd A, Carroll FI, et al. Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration. Psychopharmacology (Berl) 2011;213(4):715-22
   PubMed Web of Science ®Google Scholar
• O’Dell LE, Khroyan TV. Rodent models of nicotine reward: what do they tell us about tobacco abuse in humans? Pharmacol Biochem Behav 2009;91(4):481-8
   PubMed Web of Science ®Google Scholar
• Shaham Y, Shalev U, Lu L, et al. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 2003;168(1-2):3-20
   PubMed Web of Science ®Google Scholar
• Epstein DH, Preston KL, Stewart J, Shaham Y. Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl) 2006;189(1):1-16
   PubMed Web of Science ®Google Scholar
• Le Foll B, Chakraborty-Chatterjee M, Lev-Ran S, et al. Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used. Int J Neuropsychopharmacol 2012;15(9):1265-74
   PubMed Web of Science ®Google Scholar
• Semenova S, Stolerman IP, Markou A. Chronic nicotine administration improves attention while nicotine withdrawal induces performance deficits in the 5-choice serial reaction time task in rats. Pharmacol Biochem Behav 2007;87(3):360-8
   PubMed Web of Science ®Google Scholar
• Shoaib M, Bizarro L. Deficits in a sustained attention task following nicotine withdrawal in rats. Psychopharmacology (Berl) 2005;178(2-3):211-22
   PubMed Web of Science ®Google Scholar
• Matta SG, Balfour DJ, Benowitz NL, et al. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 2007;190(3):269-319
   PubMed Web of Science ®Google Scholar
• Moretti M, Mugnaini M, Tessari M, et al. A comparative study of the effects of the intravenous self-administration or subcutaneous minipump infusion of nicotine on the expression of brain neuronal nicotinic receptor subtypes. Mol Pharmacol 2010;78(2):287-96
   PubMed Web of Science ®Google Scholar
• O’Dell LE, Chen SA, Smith RT, et al. Extended access to nicotine self-administration leads to dependence: Circadian measures, withdrawal measures, and extinction behaviour in rats. J Pharmacol Exp Ther 2007;320(1):180-93
   PubMed Web of Science ®Google Scholar
• Kenny PJ, Markou A. Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology 2006;31(6):1203-11
   PubMed Web of Science ®Google Scholar
• Irvine EE, Bagnalasta M, Marcon C, et al. Nicotine self-administration and withdrawal: modulation of anxiety in the social interaction test in rats. Psychopharmacology (Berl) 2001;153(3):315-20
   PubMed Web of Science ®Google Scholar
• Kayir H, Semenova S, Markou A. Baseline impulsive choice predicts the effects of nicotine and nicotine withdrawal on impulsivity in rats. Prog Neuropsychopharmacol Biol Psychiatry 2014;48:6-13
   PubMed Web of Science ®Google Scholar
• Semenova S, Stolerman IP, Markou A. Chronic nicotine administration improves attention while nicotine withdrawal induces performance deficits in the 5-choice serial reaction time task in rats. Pharmacol Biochem Behav 2007;87(3):360-8
   PubMed Web of Science ®Google Scholar
• Ashare RL, Hawk LW Jr. Effects of smoking abstinence on impulsive behaviour among smokers high and low in ADHD-like symptoms. Psychopharmacology (Berl) 2012;219(2):537-47
   PubMed Web of Science ®Google Scholar
• Harrison EL, Coppola S, McKee SA. Nicotine deprivation and trait impulsivity affect smokers’ performance on cognitive tasks of inhibition and attention. Exp Clin Psychopharmacol 2009;17(2):91-8
   PubMed Web of Science ®Google Scholar
• Ashare RL, Valdez JN, Ruparel K, et al. Association of abstinence-induced alterations in working memory function and COMT genotype in smokers. Psychopharmacology (Berl) 2013;230(4):653-62
   PubMed Web of Science ®Google Scholar
• Conners CK, Erhardt D, Sparrow MA. Conners’ adult ADHD rating scales (CAARS). Multihealth Systems, Inc., New York; 1999
   Google Scholar
• Ashare RL, Falcone M, Lerman C. Cognitive function during nicotine withdrawal: implications for nicotine dependence treatment. Neuropharmacology 2014;76(Pt B):581-91
   PubMedGoogle Scholar
• Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl) 2010;210(4):453-69
   PubMed Web of Science ®Google Scholar
• Sarter M, Paolone G. Deficits in attentional control: cholinergic mechanisms and circuitry-based treatment approaches. Behav Neurosci 2011;125(6):825-35
   PubMed Web of Science ®Google Scholar
• Conners CK. Conners’ continuous performance test II (CPT II V. 5). Multi-Health Systems, North Tonawanda, NY; 2000
   Google Scholar
• Coull JT, Frith CD, Frackowiak RS, Grasby PM. A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory. Neuropsychologia 1996;34(11):1085-95
   PubMed Web of Science ®Google Scholar
• Robbins TW. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 2002;163(3-4):362-80
   PubMed Web of Science ®Google Scholar
• Baddeley A. Working memory: looking back and looking forward. Nat Rev Neurosci 2003;4(10):829-39
   PubMed Web of Science ®Google Scholar
• Owen AM, McMillan KM, Laird AR, Bullmore E. N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp 2005;25(1):46-59
   PubMed Web of Science ®Google Scholar
• Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioural characterization, pharmacological specification, and anatomic localization. Psychopharmacology 2006;184(3-4):523-39
   PubMed Web of Science ®Google Scholar
• Logan GD. On the ability to inhibit thought and action: a user’s guide to the stop signal paradigm. In: Dagenbach DaC TH, editor. Inhibitory processes in attention, memory, and language. Academic Press, San Diego; 1994. p. 189-238
   Google Scholar
• Eagle DM, Baunez C. Is there an inhibitory-response-control system in the rat? Evidence from anatomical and pharmacological studies of behavioural inhibition. Neurosci Biobehav Rev 2010;34(1):50-72
   PubMed Web of Science ®Google Scholar
• Young JW, Geyer MA, Rissling AJ, et al. Reverse translation of the rodent 5C-CPT reveals that the impaired attention of people with schizophrenia is similar to scopolamine-induced deficits in mice. Translational Psychiatry 2013;3:e324
   Web of Science ®Google Scholar
• Young JW, Light GA, Marston HM, et al. The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One 2009;4(1):e4227
   PubMedGoogle Scholar
• Izquierdo A, Jentsch JD. Reversal learning as a measure of impulsive and compulsive behaviour in addictions. Psychopharmacology (Berl) 2012;219(2):607-20
   PubMed Web of Science ®Google Scholar
• Perkins KA, Lerman C, Stitzer M, et al. Development of procedures for early screening of smoking cessation medications in humans. Clin Pharmacol Ther 2008;84(2):216-21
   PubMed Web of Science ®Google Scholar
• Perkins KA, Lerman C, Fonte CA, et al. Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clin Pharmacol Ther 2010;88(1):109-14
   PubMed Web of Science ®Google Scholar
• Perkins KA, Lerman C. An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation. Psychopharmacology (Berl) 2014;231(1):1-11
   PubMed Web of Science ®Google Scholar
• Perkins KA, Lerman C, Karelitz JL, et al. Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications. Addiction 2013;108(11):1962-8
   PubMed Web of Science ®Google Scholar
• McKee SA, Weinberger AH, Shi J, et al. Developing and validating a human laboratory model to screen medications for smoking cessation. Nicotine Tob Res 2012;2012
   Google Scholar
• McKee S, Krishnan-Sarin S, Shi J, et al. Modeling the effect of alcohol on smoking lapse behaviour. Psychopharmacology (Berl) 2006;189(2):201-10
   PubMed Web of Science ®Google Scholar
• McKee S, Sinha R, Weinberger A, et al. Stress decreases the ability to resist smoking and potentiates smoking intensity and reward. J Psychopharmacol (Oxf) 2011;25(4):490-502
   PubMed Web of Science ®Google Scholar
• Falcone M, Smith RM, Chenoweth MJ, et al. Neuroimaging in Psychiatric Pharmacogenetics Research: the Promise and Pitfalls. Neuropsychopharmacology 2013;38(12):2327-37
   PubMed Web of Science ®Google Scholar
• Jasinska AJ, Zorick T, Brody AL, Stein EA. Dual role of nicotine in addiction and cognition: A review of neuroimaging studies in humans. Neuropharmacology 2013. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Newhouse PA, Potter AS, Dumas JA, Thiel CM. Functional brain imaging of nicotinic effects on higher cognitive processes. Biochem Pharmacol 2011;82(8):943-51
   PubMed Web of Science ®Google Scholar
• Levin ED, Bradley A, Addy N, Sigurani N. Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 2002;109(4):757-65
   PubMed Web of Science ®Google Scholar
• Addy NA, Nakijama A, Levin ED. Nicotinic mechanisms of memory: effects of acute local DHbetaE and MLA infusions in the basolateral amygdala. Brain Res Cogn Brain Res 2003;16(1):51-7
   PubMedGoogle Scholar
• Gibbs RB. Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr Rev 2010;31(2):224-53
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Lowe GD, Shaper AG, et al. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005;26(17):1765-73
   PubMed Web of Science ®Google Scholar
• Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann NY Acad Sci 2010;1207:155-62
   PubMed Web of Science ®Google Scholar
• Harmey D, Griffin PR, Kenny PJ. Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. Nicotine Tob Res 2012;14(11):1300-18
   PubMed Web of Science ®Google Scholar
• Dwoskin LP, Smith AM, Wooters TE, et al. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem Pharmacol 2009;78(7):732-43
   PubMed Web of Science ®Google Scholar
• De la Garza R II, Yoon JH. Evaluation of the effects of rivastigmine on cigarette smoking by methamphetamine-dependent volunteers. Prog Neuropsychopharmacol Bol Psychiatry 2011;35(8):1827-30
   PubMed Web of Science ®Google Scholar
• Lynch WJ. Sex and ovarian hormones influence vulnerability and motivation for nicotine during adolescence in rats. Pharmacol Biochem Behav 2009;94(1):43-50
   PubMed Web of Science ®Google Scholar
• Dumas J, Hancur-Bucci C, Naylor M, et al. Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women. Neuropsychopharmacology 2006;31(9):2065-78
   PubMed Web of Science ®Google Scholar
• Dumas JA, Kutz AM, Naylor MR, et al. Estradiol treatment altered anticholinergic-related brain activation during working memory in postmenopausal women. Neuroimage 2012;60(2):1394-403
   PubMed Web of Science ®Google Scholar